Multiple Sclerosis Global Support Network News

"Your trusted source for the latest in MS news and information."

  • MS Info Hub
  • MS News

ECTRIMS 2017: Professor Till Sprenger to discuss the Aubagio Cognitive Outcomes

Dr. Lutz Achtnichts from Kantonsspital Aarau, Switzerland, caught up with Professor Till Sprenger at ECTRIMS-ACTRIMS in Paris to discuss the TEMSO study, which has...

ECTRIMS 2017: Aubagio Can Help Slow Progression to an MS Diagnosis,...

Aubagio (teriflunomide) can help to delay first clinical signs of multiple sclerosis (MS) from progressing to a definite diagnosis in a person, and treatment should...

ECTRIMS 2017: GNbAC1 Promotes Restoration of Protective Myelin Coating, Phase 2b...

GeNeuro‘s humanized antibody GNbAC1 promotes the rejuvenation of the myelin coating that protects nerve cells in patients with relapsing-remitting multiple sclerosis, or RRMS, a Phase 2 clinical trial...

ECTRIMS 2017: Promising Work in Pediatric and Secondary Progressive Patients Is...

Gilenya (fingolimod) lowered relapse rates in children and adolescents with relapsing multiple sclerosis at a “magnitude” — almost 82 percent — never before seen in...

ECTRIMS 2017: TEMSO Study Shows BVL Improvement with Teriflunomide

Data from the TEMSO study has shown that teriflunomide (Aubagio) 14 mg can significantly improve Paced Auditory Serial Addition Test (PASAT) performance in patients...

Dimethyl Fumarate as Exit Strategy From Natalizumab Treatment in Multiple Sclerosis

Patients with multiple sclerosis (MS) who are undergoing treatment with disease-modifying agents such as natalizumab are at risk of developing progressive multifocal leukoencephalopathy (PML) and rebound...

ECTRIMS 2017: Gilenya Seen to Reduce Relapses in Children with Active...

Gilenya (fingolimod) was seen to significantly reduce relapses in children and teenagers with multiple sclerosis (MS), according to data from a Phase 3 study —...

ECTRIMS 2017: Trial to See if Disease-modifying Therapies Not Necessary in...

A clinical study now enrolling people with progressive or relapsing multiple sclerosis (MS) will examine the feasibility of older patients stopping use of disease-modifying...

ECTRIMS 2017: Alemtuzumab: persistent effect over 7 years without further...

"This work is about the long-term follow-up of patients treated with alemtuzumab," explains Prof. Dr. Douglas L. Arnold of the Montreal Neurological Institute and...

ECTRIMS 2017: Alemtuzumab: only 8 days of treatment in 7 years

"It is a very effective drug, without the need for frequent administration and leading to a reduction in disability," summarizes Prof. Dr. Alasdair J....

Subscribe To Our Newsletter